Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew D Hislop

Showing results (1-10 of 46) with videos related to

Pageof 5
Sort By:
Current Opinion in Virology|September 1, 2015
Early virological and immunological events in Epstein-Barr virus infectionAndrew D Hislop
Seminars in Cancer Biology|November 15, 2008
CD8+ T cell immunity to Epstein-Barr virus and Kaposi's sarcoma-associated herpes virusAndrew D Hislop, Shereen Sabbah
Current Topics in Microbiology and Immunology|October 3, 2015
T-Cell Responses to EBVAndrew D Hislop, Graham S Taylor
Human Immunology|December 19, 2006
T-cell receptor triggering differentially regulates bim expression in human lymphocytes from healthy individuals and patients with infectious mononucleosisElena Sandalova, Andrew D Hislop, Victor Levitsky
Organic & Biomolecular Chemistry|October 7, 2006
Synthesis and biological evaluation of two chemically modified peptide epitopes for the class I MHC protein HLA-B*2705Matthew A Jones, Andrew D Hislop, John S Snaith
Plos Pathogens|September 25, 2018
Proteome-wide analysis of CD8+ T cell responses to EBV reveals differences between primary and persistent infectionCalum Forrest, Andrew D Hislop, Alan B Rickinson, et al.
Annual Review of Immunology|March 24, 2007
Cellular responses to viral infection in humans: lessons from Epstein-Barr virusAndrew D Hislop, Graham S Taylor, Delphine Sauce, et al.
Journal of Virology|March 2, 2013
Kaposi's sarcoma-associated herpesvirus-encoded viral IRF3 modulates major histocompatibility complex class II (MHC-II) antigen presentation through MHC-II transactivator-dependent and -independent mechanisms: implications for oncogenesisJianmin Zuo, Andrew D Hislop, Carol S Leung, et al.
The Journal of Experimental Medicine|February 3, 2005
CD8+ immunodominance among Epstein-Barr virus lytic cycle antigens directly reflects the efficiency of antigen presentation in lytically infected cellsVictoria A Pudney, Alison M Leese, Alan B Rickinson, et al.
Trends in Immunology|March 5, 2014
Cellular immune controls over Epstein-Barr virus infection: new lessons from the clinic and the laboratoryAlan B Rickinson, Heather M Long, Umaimainthan Palendira, et al.
Pageof 5

Showing results (1-10 of 46) with videos related to

Sort By:
Pageof 5
Current Opinion in Virology|September 1, 2015
Early virological and immunological events in Epstein-Barr virus infectionAndrew D Hislop
Seminars in Cancer Biology|November 15, 2008
CD8+ T cell immunity to Epstein-Barr virus and Kaposi's sarcoma-associated herpes virusAndrew D Hislop, Shereen Sabbah
Current Topics in Microbiology and Immunology|October 3, 2015
T-Cell Responses to EBVAndrew D Hislop, Graham S Taylor
Human Immunology|December 19, 2006
T-cell receptor triggering differentially regulates bim expression in human lymphocytes from healthy individuals and patients with infectious mononucleosisElena Sandalova, Andrew D Hislop, Victor Levitsky
Organic & Biomolecular Chemistry|October 7, 2006
Synthesis and biological evaluation of two chemically modified peptide epitopes for the class I MHC protein HLA-B*2705Matthew A Jones, Andrew D Hislop, John S Snaith
Plos Pathogens|September 25, 2018
Proteome-wide analysis of CD8+ T cell responses to EBV reveals differences between primary and persistent infectionCalum Forrest, Andrew D Hislop, Alan B Rickinson, et al.
Annual Review of Immunology|March 24, 2007
Cellular responses to viral infection in humans: lessons from Epstein-Barr virusAndrew D Hislop, Graham S Taylor, Delphine Sauce, et al.
Journal of Virology|March 2, 2013
Kaposi's sarcoma-associated herpesvirus-encoded viral IRF3 modulates major histocompatibility complex class II (MHC-II) antigen presentation through MHC-II transactivator-dependent and -independent mechanisms: implications for oncogenesisJianmin Zuo, Andrew D Hislop, Carol S Leung, et al.
The Journal of Experimental Medicine|February 3, 2005
CD8+ immunodominance among Epstein-Barr virus lytic cycle antigens directly reflects the efficiency of antigen presentation in lytically infected cellsVictoria A Pudney, Alison M Leese, Alan B Rickinson, et al.
Trends in Immunology|March 5, 2014
Cellular immune controls over Epstein-Barr virus infection: new lessons from the clinic and the laboratoryAlan B Rickinson, Heather M Long, Umaimainthan Palendira, et al.
Pageof 5